Research & Development
eMed commences administering BinaxNOW COVID-19 Ag Card rapid home test to 100,000 qualified US individuals
25 January 2021 -

eMed, a Canada-based digital health company, has commenced administering the FDA-authorised, at-home symptomatic BinaxNOW COVID-19 Ag Card rapid home test to 100,000 qualified individuals across the US who order through eMed.com, it was reported on Saturday.

The 100,000 people will be among the first to utilise the company's transformative approach to at-home testing. The company claims that they can be among the first to receive reliable and certified results from the convenience of their home in just 15 minutes. The eMed-administered rapid tests are priced at USD25 each.

The company is likely to distribute and administer 30 million tests in the first quarter of 2021 and an additional 90 million tests in the second quarter of 2021. Its digital point-of-care solutions include prescriptions, test distribution, user authentication, guided test-taking with the help from eMed certified guides, and automated and secure reporting.

Login
Username:

Password:


Related Headlines